Sangamo Therapeutics is a clinical-stage biotechnology company pioneering genomic therapies using zinc finger nucleases. It focuses on in vivo gene editing and gene regulation to treat rare genetic diseases, including hemophilia and lysosomal storage disorders. Patients with inherited conditions, particularly those affecting the blood and central nervous system, benefit from its potentially transformative treatments that aim to correct disease at the DNA level.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends